Duarte Pastora Maria de Araújo, Bastos Filho Francisco André Gomes, Duarte João Vitor Araujo, Duarte Beatrice Araújo, Duarte Isabella Araujo, Lemes Romélia Pinheiro Gonçalves, Duarte Fernando Barroso
Nefrologista no Hospital Walter Cantídio- Universidade Federal do Ceará, Fortaleza, CE, Brasil.
Graduandos do Curso de Medicina - Universidade Christus, Fortaleza, CE, Brasil.
Rev Assoc Med Bras (1992). 2020 Oct;66(10):1335-1337. doi: 10.1590/1806-9282.66.10.1335.
The COVID-19 (SARS-CoV-2) infection started in China, Wuhan City, Hubei Province, in December 2019, and it was declared a pandemic in mid-March 2020, caused by a new coronavirus strain called SARS-CoV-2. The pathogenesis of kidney injury attributed to SARS- CoV-2 is not well defined yet. Observations show that the kidney damage caused by the new virus mutation is mainly tubular, with impairment of glomerular filtration and high levels of urea and creatinine. A study with seriously ill patients with COVID-19 showed that acute kidney injury was present in 29%. In the face of this evidence, based on recent studies, we can see the great renal contribution as an impact factor in the evolution of COVID-19, not just as a complicator of severity, but maybe part of the initial cascade of the process, requiring a deeper analysis using conventional biomarkers of kidney injury and more aggressive clinical intervention in patients at risk, in an attempt to reduce mortality.
2019年12月,新型冠状病毒肺炎(COVID-19,由严重急性呼吸综合征冠状病毒2 [SARS-CoV-2]引起)在中国湖北省武汉市开始出现,并于2020年3月中旬被宣布为大流行病。SARS-CoV-2所致肾损伤的发病机制尚未完全明确。观察结果显示,这种新病毒变异导致的肾损伤主要累及肾小管,伴有肾小球滤过功能受损以及尿素和肌酐水平升高。一项针对COVID-19重症患者的研究表明,29%的患者存在急性肾损伤。鉴于这些证据,基于近期研究,我们可以看出肾脏在COVID-19病情进展中起着重要作用,它不仅是病情严重程度的一个并发症因素,或许还是疾病初始进程的一部分,这就需要使用传统的肾损伤生物标志物进行更深入的分析,并对高危患者采取更积极的临床干预措施,以降低死亡率。